Возраст домена | n/a |
Дата окончания | n/a |
PR | 4 |
ИКС | n/a |
Страниц в Google | 171000 |
Страниц в Яндексе | 353 |
Dmoz | Нет |
Яндекс Каталог | Нет |
Alexa Traffic Rank | 1507115 |
Alexa Country | 511737 |
История изменения показателей | Авторизация |
Идет сбор информации... Обновить
PipelineReview.com - The Biologics News and Reports Portal
Biologics, antibodies, proteins, biosimilars, sales, market, reports, newsletters, databases, consultancy, periodicals, newsletter, DNA, RNA, cells, antisense, vaccines, competitive intelligence, business intelligence, publishing, research & development, targets, analysis, companion diagnostics, personalized medicine, biomarkers, gene therapy, cell therapy, drug delivery, industry data
PipelineReview.com provides business information on biologics regarding R&D, markets, sales, technologies, competitors
UTF-8
33.75 КБ
592
5 016 симв.
4 339 симв.
Данные предоставлены сервисом semrush
Сайт | Общие фразы | PR | тИЦ | Alexa Rank | Alexa Country | |
---|---|---|---|---|---|---|
fiercebiotech.com | 23 | 6 |
0 | 87045 | 19580 | |
wikipedia.org | 19 | 9 |
0 | 5 | 6 | |
biomet.com | 16 | 6 |
20 | 1013879 | 392723 | |
nih.gov | 16 | 8 |
0 | 113 | 65 | |
yahoo.com | 14 | 9 |
0 | 9 | 7 | |
seekingalpha.com | 13 | 6 |
0 | 1742 | 416 | |
nature.com | 13 | 9 |
0 | 740 | 269 | |
seattlegenetics.com | 12 | 4 |
0 | 555136 | 114353 | |
linkedin.com | 12 | 9 |
0 | 25 | 10 | |
reportlinker.com | 11 | 6 |
60 | 59102 | 74971 | |
Еще 40 сайтов после авторизации |
Данные предоставлены сервисом semrush
Счетчик | Посетители за 24 часа | Просмотры | Просмотров на посетителя |
---|---|---|---|
Google Analytics | Нет доступа | Нет доступа | n/a |
Данные linkpad ( 28 Февраля 2013 ) | |
Количество ссылок на сайт | 1457 |
Количество доменов, которые ссылаются на сайт | 76 |
Количество найденных анкоров | 104 |
Исходящие (внешние) ссылки домена | 1780 |
Количество доменов, на которые ссылается сайт | 46 |
Количество исходящих анкоров | 15 |
Внешние ссылки главной страницы ( 9 ) | |
lamerie.com/ | <img> |
lamerie.com/free-reports-list/ | FREE reports |
lamerie.com/report/next-wave-biosimilar-antibodies-of-lucent... | Competitor Analysis: Next Wave Biosimilar Antibodies of Lucentis, Eylea, Xolair, Prolia, Stelara, Soliris and More |
lamerie.com/report/rna-targeted-small-molecules-2019-a-lands... | RNA-Targeted Small Molecules 2019: a landscape analysis of companies, technologies, targets, investors and partners from an indu... |
lamerie.com/report/bispecific-antibodies-for-immuno-oncology... | Bispecific Antibodies for Immuno-Oncology & Other Diseases |
lamerie.com/report/t-cell-nk-cell-engaging-bispecific-antibo... | T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: a business, stakeholder, technology and pipeline analysis |
lamerie.com/report/cd38-targeted-antibody-cell-therapy/ | CD38-Targeted Antibody & Cell Therapy |
lamerie.com/newsletter-signup/ | Sign Up |
lamerie.com/report/blockbuster-biologics-2018-sales-of-recom... | Get it now |
Внутренние ссылки главной страницы ( 44 ) | |
/index.php/my-cart | My cart / Checkout |
/ | Home |
/index.php/contact-us-2 | Contact Us |
/index.php/News-Channels/ | More News... |
/index.php/Table/News-Channels/Antibodies/ | Antibodies |
/index.php/Table/News-Channels/DNA-RNA-and-Cells/ | DNA, RNA & Cells |
/index.php/Table/News-Channels/Proteins-and-Peptides/ | Protein & Peptides |
/index.php/Table/News-Channels/Small-Molecules/ | Small Molecules |
/index.php/Table/News-Channels/Vaccines/ | Vaccines |
/index.php/Table/News-Channels/More-News/ | More News |
/index.php/reports | All Products |
/index.php/reports/antibody-protein-sales | Antibody & Protein Sales |
/index.php/reports/antibody-technologies | Antibody Technologies |
/index.php/reports/biosimilar-antibodies-proteins | Biosimilar Antibodies & Proteins |
/index.php/reports/car-t-cells-nk-cells | CAR T-Cells & NK Cells |
/index.php/reports/immuno-oncology | Immuno-Oncology |
/index.php/reports/mrna-vaccines-therapeutics | mRNA Vaccines & Therapeutics |
/index.php/reports/pipeline-database | Pipeline Database |
/index.php/reports/target-pipelines | Target Pipelines |
/index.php/reports/tcr-t-cells-and-antibodies | TCR T-Cells and Antibodies |
/index.php/reports/therapeutic-proteins-peptides | Therapeutic Proteins & Peptides |
/index.php/reports/vaccines | Vaccines |
/index.php/Offers.html | Offers |
/index.php/Table/Press-Room/ | Press Room |
/index.php/2005120240/About-Us.html | About Us |
/index.php/2019122773381/More-News/Astellas-Strengthens-Immu... | Astellas Strengthens Immuno-oncology Pipeline with Acquisition of Xyphos Biosciences, Inc. |
/index.php/2019122373364/Small-Molecules/U.S.-FDA-Approves-E... | U.S. FDA Approves Eisai's DAYVIGO™ (lemborexant) for the Treatment of Insomnia in Adult Patients |
/index.php/2019122373363/Small-Molecules/Seattle-Genetics-An... | Seattle Genetics Announces Submission of Tucatinib New Drug Application to the U.S. FDA for Patients with Locally Advanced or Me... |
/index.php/2019122873384/Antibodies/China-National-Medical-P... | China National Medical Products Administration Approves BeiGene’s Tislelizumab for Patients with Classical Hodgkin’s Lymphoma Wh... |
/index.php/2019122873383/Antibodies/First-Patient-Dosed-in-P... | First Patient Dosed in Phase 1 Clinical Study of Tafasitamab in Firstline DLBCL |
/index.php/2019122773382/Vaccines/Sinovac-Announces-Approval... | Sinovac Announces Approval of Varicella Vaccine for Prevention of Varicella-Zoster Virus (Chickenpox) in Children |
/index.php/2019122673380/Small-Molecules/Spring-Bank-Stops-D... | Spring Bank Stops Dosing of Inarigivir Patients in Phase 2 Program |
/index.php/2019122673379/DNA-RNA-and-Cells/Prevail-Therapeut... | Prevail Therapeutics Announces IND Active for PR001 for Treatment of Neuronopathic Gaucher Disease |
/index.php/2019122673378/Antibodies/Immunomedics-Announces-F... | Immunomedics Announces FDA Acceptance for Filing of Biologics License Application Resubmission for Sacituzumab Govitecan to Trea... |
/index.php/2019122673377/Small-Molecules/Spectrum-Pharmaceut... | Spectrum Pharmaceuticals Provides Pipeline Update on Late Stage Programs |
/index.php/2019122473376/Small-Molecules/Allergan-Receives-U... | Allergan Receives U.S. FDA Approval for UBRELVY™ for the Acute Treatment of Migraine with or without Aura in Adults |
/index.php/2019122473375/More-News/NewLink-Genetics-Announce... | NewLink Genetics Announces Exclusive Worldwide License Agreement with Ellipses Pharma for Development of and Rights to Commercia... |
/index.php/2019122473374/More-News/Gilead-and-Eisai-Enter-In... | Gilead and Eisai Enter Into Agreement in Japan for the Co-Promotion of the Investigational Rheumatoid Arthritis Therapy Filgotin... |
/index.php/2019122373373/More-News/Sarepta-Therapeutics-Anno... | Sarepta Therapeutics Announces Partnership with Roche in Territories Outside the United States for its Investigational Micro-dys... |
/index.php/2019122373372/Small-Molecules/Trevena-Announces-I... | Trevena Announces Initiation of Proof-of-Concept Study for TRV734 for Potential Treatment of Opioid Use Disorder |
/index.php/2012051731797/Terms-and-Conditions.html | Terms and Conditions |
/index.php/20120517591/Privacy-Policy.html | Privacy Policy |
/index.php/2005120242/Submit-your-Press-Release.html | Submit your Press Release |
/index.php/2012051744/Imprint.html | Imprint |
[Querying whois.verisign-grs.com]
[Redirected to whois.godaddy.com]
[Querying whois.godaddy.com]
[whois.godaddy.com]
The data contained in GoDaddy.com, LLC's WhoIs database,
while believed by the company to be reliable, is provided "as is"
with no guarantee or warranties regarding its accuracy. This
information is provided for the sole purpose of assisting you
in obtaining information about domain name registration records.
Any use of this data for any other purpose is expressly forbidden without the prior written
permission of GoDaddy.com, LLC. By submitting an inquiry,
you agree to these terms of usage and limitations of warranty. In particular,
you agree not to use this data to allow, enable, or otherwise make possible,
dissemination or collection of this data, in part or in its entirety, for any
purpose, such as the transmission of unsolicited advertising and
and solicitations of any kind, including spam. You further agree
not to use this data to enable high volume, automated or robotic electronic
processes designed to collect or compile this data for any purpose,
including mining this data for your own personal or commercial purposes.
Please note: the registrant of the domain name is specified
in the "registrant" field. In most cases, GoDaddy.com, LLC
is not the registrant of domain names listed in this database.
Registered through: GoDaddy.com, LLC (http://www.godaddy.com)
Domain Name: PIPELINEREVIEW.COM
Registrant:
Domains By Proxy, LLC
Domain servers in listed order:
NS51.DOMAINCONTROL.COM
NS52.DOMAINCONTROL.COM
For complete domain details go to:
http://who.godaddy.com/whoischeck.aspx?domain=PIPELINEREVIEW.COM
# If the Joomla site is installed within a folder such as at
# e.g. www.example.com/joomla/ the robots.txt file MUST be
# moved to the site root at e.g. www.example.com/robots.txt
# AND the joomla folder name MUST be prefixed to the disallowed
# path, e.g. the Disallow rule for the /administrator/ folder
# MUST be changed to read Disallow: /joomla/administrator/
#
# For more information about the robots.txt standard, see:
# http://www.robotstxt.org/orig.html
#
# For syntax checking, see:
# http://www.sxw.org.uk/computing/robots/check.html
User-agent: *
Disallow: /administrator/
Disallow: /cache/
Disallow: /cli/
Disallow: /components/
Disallow: /images/
Disallow: /includes/
Disallow: /installation/
Disallow: /language/
Disallow: /libraries/
Disallow: /logs/
Disallow: /media/
Disallow: /modules/
Disallow: /plugins/
Disallow: /t3-assets/
Disallow: /templates/
Disallow: /tmp/
Disallow: /publisher/
Disallow: /press-room/
Disallow: /pipeline_samples/
Disallow: /onlinestore/
Disallow: /store/
Disallow: /img/
Disallow: /freetrial/
Disallow: /2012/
Disallow: /database/
Disallow: /free-downloads/
Disallow: /newsletter/
Disallow: /products/
Disallow: /report2007/
Франция - Булонь-Бийанкур - 85.31.219.2
Jaguar Network SAS
Jaguar Network SAS
HTTP/1.1 200 OK
Server: nginx
Date: Mon, 30 Dec 2019 05:26:23 GMT
Content-Type: text/html; charset=utf-8
Transfer-Encoding: chunked
Connection: keep-alive
X-Powered-By: PHP/5.6.40
P3P: CP="NOI ADM DEV PSAi COM NAV OUR OTRo STP IND DEM"
Cache-Control: no-cache
Pragma: no-cache
Set-Cookie: cdbb604521ec2975cb17c63c28a00c28=333fcc4111e86459f3e1e4fea34e59d6; path=/
Vary: Accept-Encoding
X-Powered-By: PleskLin
Кнопка для анализа сайта в один клик, для установки перетащите ссылку на "Панель закладок"